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article under the CC BY-NC-ND license (Abstract Background/purpose: Bone resorption and inhibition of bone formation occur on
the compressed side during orthodontic tooth movement. Bone formation inhibitory factors
such as sclerostin (encoded by SOST ) are secreted on the compressed side by periodontal lig-
ament (PDL) cells. PDL cells control bone metabolism, and compressed PDL cells inhibit bone
formation during orthodontic tooth movement. The aim of this study was to identify the inhib-
itory factors of bone formation in PDL cells.
Materials and methods: Changes in SOST expression and subsequent protein release from hu-
man PDL (hPDL) cells were assessed using the real-time polymerase chain reaction (PCR), semi-
quantitative PCR, and immunofluorescence in hPDL cells subjected to centrifugal force (40g
and 90g). To confirm the effects on bone formation, human alveolar bone-derived osteoblasts
(hOBs) were grown with the addition of sclerostin peptide. In vivo, a compressive force was
applied using the Waldo method in rats, and the distribution of sclerostin in PDL tissues was
examined by immunohistochemistry.
Results: SOST expression was downregulated in vitro by centrifugation at 90g for 24 hours but
upregulated by centrifugation at 40g based on real-time PCR, as was confirmed by immunoflu-
orescence staining. The addition of sclerostin peptide significantly decreased the mineralized
area in hOBs. However, slightly weakly sclerostin-positive PDL cells were observed on the com-
pressed side in vivo.
Conclusion: These results indicate that PDL cells subjected to light compressive force exhibit
increased expression of SOST/sclerostin, which inhibits bone formation on the compressed side
during orthodontic tooth movement.
Copyright ª 2016, Association for Dental Sciences of the Republic of China. Published by Else-
vier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Orofacial Functions and Orthodontics, Kyushu Dental University, 2-6-1, Manazuru, Kokurakita-ku
.ac.jp (K.N. Kuroishi).
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Applying orthodontic force to teeth results in their move-
ment. During this process, bone resorption is dominant on
the compression side, and bone formation is dominant on
the tension side. Once mechanical forces are applied, the
root moves close to the alveolar wall, resulting in a
reduction of vasculature to the area.1 Then, a cell-free
zone or hyalinized area is temporarily formed. These
areas must be removed to allow the teeth to move.2 To
maintain the optimal periodontal ligament (PDL) distance,
PDL cells on the compressed side release osteoclast-
inductive molecules, causing osteoclast resorption of
alveolar bone. If excessive force is applied, the root of the
tooth and alveolar bone become attached, resulting in
ankylosis.3,4 To avoid ankylosis, compressed PDL cells
secrete factors that inhibit osteoblasts as well as activating
factors for osteoclasts.
Regarding the effects of mechanical stress on osteo-
blastic bone formation, previous reports indicated that
compressive force (CF) activates osteoblastic bone for-
mation.5e7 However, during orthodontic tooth movement,
no activation of bone formation is observed on the com-
pressed side. These contradictory findings suggest that
bone formation on the compression side is likely to be
inhibited by compressed PDL cells. The most likely candi-
date molecule for osteoblastic bone formation inhibition by
PDL cells is sclerostin (encoded by SOST ).8,9 SOST/sclero-
stin inhibits bone formation by inhibiting Wnt signaling.
Sclerostin is a Wnt antagonist that has been identified as an
inhibitor of canonical Wnt signaling, and Wnt signaling and
sclerostin are blocked by preventing the formation of Wnt-
Fizzled (Fz)-lipoprotein receptor-related protein (LRP) 5/6
complexes.10e15 That is, sclerostin inhibits the binding of
the Wnt receptor by interacting with LRP5/6, and sup-
presses bone formation. However, the molecules involved
in the inhibition of bone formation on the compressed side
during orthodontic tooth movement remain unknown.
We investigated the changes in SOST/sclerostin expres-
sion and the inhibitory effects on bone formation of PDL
cells subjected to mechanical CF.
Materials and methods
Human periodontal ligament (hPDL) cells were isolated
from healthy PDLs of premolar teeth that were extracted
for orthodontic reasons. All patients gave informed consent
prior to providing samples. All cells were cultured in Alpha
Minimum Essential Medium (aMEM; Gibco-BRL, Grand Is-
land, NY, USA) supplemented with 10% fetal bovine serum
(Cellgro; Mediatech Inc., Herndon, VA, USA), 50 U/mL
penicillin G (Gibco-BRL), 50 mg/mL fungizone (Gibco-BRL),
and 50 mg/mL gentamicin (Gibco-BRL), and incubated at
37C in a 5% CO2 incubator. Cells underwent three to eight
passages prior to use in experiments. All procedures were
approved by the Research Ethics Committee of Kyushu
Dental University (Kitakyushu, Japan; permission number,
14-8).
We performed reproduction of the compressed side
during clinical orthodontic tooth movement by centrifuga-
tion because centrifugation enables sufficient externalmechanical stimulation, as described in previous stud-
ies.16e18 We applied centrifugation according to the pro-
cedure described by Redlich et al,19 with some
modifications. When cells reached subconfluence in culture
flasks (Becton Dickinson, San Jose, CA, USA), the medium
was changed to HEPES-buffered Dulbecco’s modified Ea-
gle’s medium without bicarbonate (Invitrogen Co., Carls-
bad, CA, USA), and 90 mL HCl (Nacalai Tesque Inc., Kyoto,
Japan) was added to stabilize the pH. Cells were then
incubated at 37C (Yamato Scientific Co., Ltd., Tokyo,
Japan) for 24 hours. Next, cell-culture flasks were centri-
fuged at 40 and 90 g (Kubota Co., Tokyo, Japan) at 37C for
24 hours.
Force was calculated using the following equation:
PZ

m r rpm2 p2ðA 9:8 900Þ; ð1Þ
where P is kg compression/cm2 of cells;m is the mass of the
medium (0.005 kg); r is the radius (0.1 m); rpm denotes
revolution/min (40 g and 90 g); and A is the area of contact
between the medium and cells (12.5 cm2). The CFs of 40g
and 90g correspond to 16.1 g/cm2 and 36.2 g/cm2,
respectively.
RNA was isolated from CF-treated hPDL cells and purified
using RNAqueous Total RNA Isolation Kit (Ambion) according
to the manufacturer’s instructions. Total RNA from CF-
treated hPDL cells was treated with DNase and reverse-
transcribed with random primers using a Superscript First-
Strand Kit (Invitrogen Co.). Real-time polymerase chain
reaction (RT-PCR) was performed using the TaqMan Gene
Expression Assay (Applied Biosystems, Foster City, CA, USA)
and Eco Real Time PCR System (Illumina, San Diego, CA,
USA). mRNA detection was performed using predeveloped
proprietary TaqMan primers [b-actin (ACTB:
Hs99999903_m1) and SOST (SOST: Hs00228830_m1); Applied
Biosystems]. These analyses were conducted to determine
the levels of b-actin for data normalization. The cycling
conditions were 95C for 15 seconds and 60C for 60 sec-
onds, for 40 cycles. The expression levels of target genes
were normalized to b-actin expression and are presented
relative to the control.
RNA was isolated from CF-treated hPDL cells as
described above, followed by DNase digestion. cDNA was
synthesized from 2 mL total RNA in 30 mL reaction buffer
containing 500mM dNTPs, 20 U ribonuclease inhibitor
(Promega, Madison, WI, USA), and 200 U Superscript II
Reverse Transcriptase (Invitrogen Co., Life Technologies).
The following primers were used for amplification: GAPDH,
50-TGA AGG TCG GTG TCA ACG GA-30 and 50-TAC TGG TGT
CAG GTA CGG TAG-30; SOST, 50-GGA CTC CAG TGC CTT TTG
AA-30 and 50 Z-GTT CCA GTG AAG GTC TTA AGT C-30. The
PCR program consisted of an initial denaturation step
(GAPDH and SOST, 94C for 2 minutes) followed by 40 cy-
cles of denaturation (GAPDH, 94C for 30 seconds; SOST,
94C for 60 seconds), annealing (GAPDH, 55C for 1 min-
ute; SOST, 62C for 1 minute), and extension at 72C for
1 minute. The PCR products were subjected to electro-
phoresis in 5% agarose gels and visualized with ethidium
bromide. GAPDH expression was used as an internal
control.
Next, the release of sclerostin was determined by
enzyme-linked immunosorbent assay (ELISA) using culture
medium from hPDL cells treated with/without CF. hPDL
Figure 1 Effects of CF on SOST expression in hPDL cells. (A)
Quantitative expression of SOST mRNA in hPDL cells subjected
to a CF of 40g for 24 hours was analyzed by real-time PCR. Data
indicate expression relative to the control (b-actin) (n Z 5).
Values are presented as the means  SE. * P < 0.01. (B) RT-PCR
analysis of SOST mRNA expression in CF-treated hPDL cells. CF
was applied at 40g for 24 hours. SOST mRNA expression was
analyzed relative to GAPDH expression. (C) Enzyme-linked
immunosorbent assay (ELISA) analysis was used to determine
the amount of sclerostin in the supernatant of CF-treated cells
(40g) for 24 hours (n Z 10). Values are presented as the
means  SEM. * P < 0.01. CF Z compressive force;
hPDL Z human PDL; PDL Z periodontal ligament; RT-
PCR Z real-time polymerase chain reaction; SEM Z standard
error of the mean.
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from each sample was pipetted into 96-well plastic plates
and incubated at 4C overnight. After incubation, the
plates were washed with phosphate buffered saline (PBS)e
Tween (0.5%, Tween 20) and blocked with Blocking One
(Nacalai Tesque Inc.) for 30 minutes at room temperature.
The plates were then incubated with a sclerostin antibody
[rabbit polyclonal immunoglobulin IgG, 1:500; Santa Cruz
Biotechnology, Santa Cruz, CA, USA; sc-130258] for 1 hour
at room temperature. After washing, donkey antigoat IgG-
horseradish peroxidase (1:5000 dilution; Santa Cruz
Biotechnology) was added and incubated for 1 hour at room
temperature. After further washes, alkaline phosphatase
activity was detected by ELISA in the buffer. The ELISA
buffer was obtained by adding OPD tablets (Wako, Osaka,
Japan) and 4 mL H2O2 in 12 mL 0.1M citrate phosphate
buffer. The optical density was measured at 490 nm using a
microplate reader (Bio-Rad Laboratories Inc., Hercules, CA,
USA).
hPDL cells treated with/without CF were fixed with 4%
paraformaldehyde (PFA). The distribution of sclerostin was
also examined immunocytochemically using rabbit poly-
clonal antisclerostin (1:100 dilution; Santa Cruz Biotech-
nology) as the primary antibody and goat antirabbit IgG
(1:400 dilution; Invitrogen Co., Life Technologies) as the
secondary antibody. Cell nuclei were stained with 40,6-
diamidino-2-phenylindole (DAPI; Vector Laboratories Inc.,
Burlingame, CA, USA).
Male SpragueeDawley (SD) rats weighing 200e250 g
were used for all in vivo experiments. All procedures were
approved by the Animal Research Committee of Kyushu
Dental University (permission number, 15-004). An elastic
band was inserted into male SD rats between their first and
second upper molars. Untreated animals were used as a
control group. Rats were then perfused through the left
ventricle with 4% PFA in 0.2M phosphate buffer (pH 7.4)
containing 0.2% picric acid.20 Maxillary bones, including
upper molars, were then removed, postfixed with PFA
overnight, decalcified with 10% EDTA solution, and
embedded in paraffin; then 5-mm horizontal sections of the
molars in the maxilla were prepared. The distribution of
sclerostin was also examined immunohistochemically using
the same procedure. Positive reactions were visualized
with 0.02% 3,30-diaminobenzidine (DAB; Dojindo, Kuma-
moto, Japan) and 0.02% hydrogen peroxidase solution
(Wako).
Finally, human alveolar bone-derived osteoblasts
(hOBs; Cell Applications Inc., San Diego, CA, USA) were
grown in 24-well plates at a density of 2.0  104 cells/well.
After reaching near-confluence, half the medium was
replaced with the supernatant of the culture medium
taken from hPDL cells treated with/without CF. Alterna-
tively, sclerostin peptide (Acris Antibodies GmbH, Herford,
Germany) was added to confirm the effects on bone for-
mation based on the sclerostin protein concentration as
determined by ELISA. We used this sclerostin peptide
referring to the characterization of sclerostin described by
Veverka et al.21 The medium was changed every 3 days,
and cells were cultured for 4 weeks. After incubation,
hOBs were washed with PBS and fixed with 4% PFA for
10 minutes at room temperature. After washing, hOBs
were treated with 5% silver nitrate solution for 30 minutesat room temperature. After further washes, hOBs were
fixed with 3% sodium thiosulfate solution for 5 minutes at
room temperature. The plates were dried for 12 hours
after washing. Quantitative data were obtained by Image J
(NIH, Bethesda, MD, USA) analysis of the images taken with
a microscope.
Statistical analysis
One-way analysis of variance followed by individual post
hoc comparisons (Scheffe´) was used to analyze significant
differences.
Results
To evaluate the differential mRNA expression patterns of a
bone formation inhibitory factor, SOST mRNA expression in
hPDL cells treated with/without CF (40g and 90g) was
measured using real-time RT-PCR (Figure 1A). Although 90g
CF-treated hPDL cells exhibited lower SOST mRNA
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expression of SOST mRNA compared to the control. In
addition, to investigate the effect of CF (40g), we used RT-
PCR to determine the expression of SOST mRNA in hPDL
cells treated with CF (40g; Figure 1B). SOST mRNA expres-
sion increased in 40g CF-treated hPDL cells based on both
real-time PCR and RT-PCR; SOST mRNA expression was
significantly decreased when cells were treated with 90g.
Next, we used ELISA to determine the levels of sclerostin
released from CF-treated hPDL cells. We found that hPDL
cells secreted significantly higher levels of sclerostin
(mean, 2.3 ng/mL) compared with controls (mean, 1.3 ng/
mL; Figure 1C).
To confirm the distribution of sclerostin in cultured hPDL
cells, immunofluorescence labeling was used. Similar to the
increase in SOST mRNA expression in hPDL cells treated
with 40g CF (Figure 2B), hPDL cells subjected to CF showed
greater sclerostin immunopositivity than the controls.
Conversely, cells treated with a CF of 90g exhibited lower
sclerostin immunopositivity (Figure 2C) compared to un-
treated cells (Figure 2A), consistent with the decreased
SOST mRNA expression based on real-time PCR.
We assessed sclerostin localization in PDL tissues of SD
rats by using an elastic band between their first and second
upper molars to apply orthodontic force. Immunopositive
staining for sclerostin was a little scarce in PDL tissues
(Figure 3D) compared to the control (Figure 3A). Slightly
weak immunopositive staining for sclerostin was also
confirmed in the compressed (Figure 3E) and tension PDL
tissues (Figure 3F), as well as on the mesial (Figure 3B) and
distal sides (Figure 3C) in coronal tissues of the first upper
molar distal root.
To examine the inhibitory effects of bone formation by
hPDL cells, hOBs were cultured with the supernatant from
hPDL cells treated with 40g CF for 4 weeks. The mineralized
area was significantly decreased in hOBs cultured with the
supernatant from CF-treated cells compared to cells
cultured with the supernatant from untreated cells (Figures
4Ae4C). Finally, to confirm that the inhibitory effects were
attributable to sclerostin, hOBs were cultured with sclero-
stin peptide (1.3 ng/mL or 2.3 ng/mL). We determined that
sclerostin peptide concentrations at 1.3 ng/mL and 2.3 ng/
mL were equivalent to the control and centrifuged levels of
sclerostin, respectively (Figure 1C). The addition of 2.3 ng/
mL sclerostin significantly decreased the mineralized area
compared to cells cultured with 1.3 ng/mL sclerostin
(Figures 4De4F).Figure 2 Immunocytochemical localization of sclerostin in CF-t
(green) and hPDL cell nuclei (blue). Control cells (A) and CF-treated
CF Z compressive force; hPDL Z human periodontal ligament.Discussion
We determined the bone-formation inhibitory effects of
SOST/sclerostin produced by PDL cells subjected to light CF
during orthodontic tooth movement. SOST was found to be
an important factor in the prevention of ankylosis on the
compressed side.22,23 SOST/sclerostin is a candidate factor
in the inhibition of bone formation.8,9 SOST/sclerostin in-
hibits the binding of Wnt receptor by interacting with LRP5/
6 and suppresses bone formation.10e15 In the present study,
we showed that SOST/sclerostin in PDL cells is likely to be
involved in the inhibition of bone formation on the com-
pressed side during orthodontic tooth movement.
In vitro, we confirmed the expression of SOST/sclerostin
in hPDL cells without CF. Expression of SOST/sclerostin in
hPDL cells increased significantly under a CF of 40g, but
decreased under a CF of 90g based on real-time PCR. These
results were confirmed by immunocytochemical staining of
hPDL cells subjected to CF. Additionally, the release of
sclerostin in hPDL cells significantly increased under a CF of
40g based on ELISA. Therefore, we concluded that the CF
needed for high SOST/sclerostin expression and release is
40g (16.1 g/cm2), which differs slightly from the optimal
clinical orthodontic force (33.5 g/cm2).24
In vivo, slightly weak immunoreactivity for sclerostin
was found on the compressed side of the periodontium of
rat molars. This may have been due to the excessive CF
induced by using an elastic band25; further studies are
required with a rat model that allows light CF to be applied.
These findings suggest that SOST expression and sclero-
stin release by PDL cells are increased during light CF,
which might have an effect on osteoblasts and bone
formation.
To investigate the inhibitory effects on bone formation
of SOST/sclerostin released by CF-treated PDL cells, we
examined the effects on bone formation using hOBs with/
without the supernatant from 40g CF-treated hPDL cells or
sclerostin peptide. We found that the mineralized area was
significantly decreased in hOBs cultured with the superna-
tant from 40g CF-treated hPDL cells compared to hOBs
cultured with the supernatant from untreated hPDL cells.
Furthermore, compared to the control, the mineralized
area was significantly decreased in hOBs by addition of
sclerostin peptide.
We found that the maximum SOST expression in PDL cells
occurred at 40g (16.1 g/cm2), and the expression of SOST/
sclerostin in hPDL cells decreased after exposure to a CF ofreated hPDL cells. Immunocytochemical staining of sclerostin
cells [(B) 40g for 24 hours; (C) 90g for 24 hours]. BarsZ 50 mm.
Figure 3 Localization of sclerostin in rat PDL tissues. Elastic bands were placed between the first (M1) and second molars (M2) of
SD rats according to the Waldo method. DAB staining of sclerostin. (AeC) Control tissues without CF, including mesial (B) and distal
(C) sides in coronal tissues of the M1 distal root. (DeF) Tissues with CF, including compressed (E) and tension tissues (F) by the
Waldo method. Slightly weak immunopositive staining for sclerostin was confirmed on the mesial (B), distal (C), compressed (E),
and tension (F) sides in PDL tissues of the M1 distal root. CF Z compressive force; DAB Z 3,30-diaminobenzidine; hPDL Z human
PDL; M1 Z first molar; P Z dental pulp; PDL Z periodontal ligament; R Z tooth root; SDZ SpragueeDawley. Bars Z 100 mm.
276 M. Ueda et al90g (36.2 g/cm2), which is close to the optimal clinical or-
thodontic force (33.5 g/cm2).24 Generally, continuous force
is the main mechanism of orthodontic tooth movement, but
the degree of force decreases slowly over time. Therefore
we suggest that the production of bone-formationinhibitory factors such as SOST/sclerostin by PDL cells in-
creases when the level of continuous force decreases, i.e.,
when subjected to light CF, which may inhibit alveolar bone
formation at the periodontal space on the side to which
light CF is applied during orthodontic tooth movement. We
Figure 4 Changes in the mineralization of human osteoblast
cells by CF. von Kossa staining was performed after culturing
human osteoblast-like cells in medium plus the supernatant
from hPDL cells without (A) and with CF (B). von Kossa staining
was performed after culturing human osteoblast-like cells in
medium from hPDL cells plus the amount of sclerostin protein
produced without (D) and with CF (E). Comparison of changes
in the area of von Kossa-positive staining (C, F; n Z 10).
Bars Z 1 mm. Values are presented as the means  SE. *
P < 0.05, ** P < 0.01. CFZ compressive force; hPDLZ human
periodontal ligament; SE Z standard error.
Changes in SOST/sclerostin expression in PDL cells 277suggest that other antiosteogenic factors might play roles
under optimal clinical orthodontic force.26,27
In conclusion, SOST expression and sclerostin release by
PDL cells increase when they are subjected to light CF,
which inhibits bone formation by osteoblasts. That is to say,
SOST/sclerostin may contribute to inhibition of bone for-
mation on the compressive side during orthodontic treat-
ment, and support bone metabolism.Conflicts of interest
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